Related Experiment Video
Updated: Aug 17, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
New agents in intravesical chemotherapy of superficial bladder cancer
Frank G E Perabo1, Stefan C Müller
1Department of Urology, University Hospital, Bonn, Germany. perabo@lycos.com
Abstract:
Although intravesical chemotherapy has been used in the management of superficial bladder cancer for some decades, until recently there has been little or no progress in the search for new agents. However, in the past few years there have been developments of investigational drugs that may play a future role in this indication. This review highlights the mode of action, indications, dose and administration, efficacy, safety and significance of new chemotherapeutic agents such as intravesical valrubicin, gemcitabine, suramin, gamma-linolenic acid, eflornithine (DFMO), tipifarnib (R115777), fenritinide and celecoxib. Although the initial results achieved with these agents in clinical development seem encouraging, long-term data on the prevention of recurrence, disease progression and survival have yet to be obtained.
Insights
New intravesical chemotherapy agents show promise for superficial bladder cancer treatment. Further long-term studies are needed to confirm efficacy in preventing recurrence, progression, and improving survival rates.
Area of Science:
- Urology
- Oncology
- Pharmacology
Background:
- Intravesical chemotherapy is a long-standing treatment for superficial bladder cancer.
- Recent years have seen limited advancements in novel intravesical agents for this condition.
Purpose of the Study:
- To review emerging intravesical chemotherapeutic agents for superficial bladder cancer.
- To highlight their mechanisms, efficacy, safety, and potential future role.
Main Methods:
- Review of investigational drugs including valrubicin, gemcitabine, suramin, gamma-linolenic acid, eflornithine (DFMO), tipifarnib (R115777), fenritinide, and celecoxib.
- Analysis of their mode of action, indications, dosage, administration, efficacy, and safety profiles.
Main Results:
- Several new agents show encouraging initial results in clinical development for superficial bladder cancer.
- These agents represent potential advancements in intravesical chemotherapy.
Conclusions:
- Emerging intravesical agents offer new therapeutic avenues for superficial bladder cancer.
- Long-term data on recurrence prevention, disease progression, and survival are essential for definitive evaluation.